These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22726205)

  • 1. Usefulness of insulin detemir in Japanese children with type 1 diabetes.
    Jinno K; Urakami T; Horikawa R; Kawamura T; Kikuchi N; Kikuchi T; Kizu R; Kosaka K; Mizuno H; Mochizuki T; Nishii A; Ohki Y; Soneda S; Sugihara S; Tatematsu T; Amemiya S;
    Pediatr Int; 2012 Dec; 54(6):773-9. PubMed ID: 22726205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
    Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
    Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
    Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
    Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
    Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
    Kabadi UM
    Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
    Päivärinta M; Tapanainen P; Veijola R
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.
    Braun D; Konrad D; Lang-Muritano M; Schoenle E
    Pediatr Diabetes; 2008 Aug; 9(4 Pt 2):382-7. PubMed ID: 18331413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
    Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
    Tan CY; Wilson DM; Buckingham B
    Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
    Le Floch JP; Lévy M; Mosnier-Pudar H; Nobels F; Laroche S; Gonbert S; Eschwege E; Fontaine P;
    Diabetes Care; 2009 Jan; 32(1):32-7. PubMed ID: 18945928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experiences with basal analogue insulin in routine care. Retrospective follow up analysis of a database from daily routine care].
    Sudár Z; Muth L; Nyirati C; Szí V; Tornóczky J; Ulrich G
    Orv Hetil; 2013 Sep; 154(37):1476-84. PubMed ID: 24016754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
    Philis-Tsimikas A
    Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.